# Aspire-Lakewood Holdings, Inc.: financial statements, quarterly

ASBP · Nasdaq · CIK 1847345 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asbp.md) · [Financials](/companies/asbp/financials.md) · [Filings](/companies/asbp/filings.md) · [Insiders](/companies/asbp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asbp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-25-023619.md) | [0.0 d](/filings/0001493152-26-015737.md) | [0.0](/filings/0001493152-26-023802.md) | [0.1](/filings/0001493152-26-037819.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-25-023619.md) | [0.0 d](/filings/0001493152-26-015737.md) | [0.0](/filings/0001493152-26-023802.md) | [0.1](/filings/0001493152-26-037819.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-25-023619.md) | [(0.0) d](/filings/0001493152-26-015737.md) | [0.0](/filings/0001493152-26-023802.md) | [(0.0)](/filings/0001493152-26-037819.md) |
| Research and development | $m | not reported | not reported | [0.0](/filings/0001641172-25-023566.md) | [0.0](/filings/0001641172-25-023573.md) | [0.0](/filings/0001493152-25-023619.md) | [0.1 d](/filings/0001493152-26-015737.md) | [0.3](/filings/0001493152-26-023802.md) | [0.4](/filings/0001493152-26-037819.md) | [0.2](/filings/0001493152-25-023619.md) | [0.1 d](/filings/0001493152-26-015737.md) | [0.3](/filings/0001493152-26-023802.md) | [0.2](/filings/0001493152-26-037819.md) |
| Operating income | $m | not reported | not reported | not reported | not reported | [(0.2)](/filings/0001493152-25-023619.md) | [(0.7) d](/filings/0001493152-26-015737.md) | [(15.6)](/filings/0001493152-26-023802.md) | [(0.8)](/filings/0001493152-26-037819.md) | [(1.1)](/filings/0001493152-25-023619.md) | [(1.8) d](/filings/0001493152-26-015737.md) | [(1.6)](/filings/0001493152-26-023802.md) | [(2.7)](/filings/0001493152-26-037819.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001493152-26-023802.md) | [0.5](/filings/0001493152-26-037819.md) | [1.5](/filings/0001493152-25-023619.md) | [6.2 d](/filings/0001493152-26-015737.md) | [1.6](/filings/0001493152-26-023802.md) | [0.0 d](/filings/0001493152-26-037819.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001493152-25-023619.md) | [0.0 d](/filings/0001493152-26-015737.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(0.1)](/filings/0001493152-24-045850.md) | [(0.2) d](/filings/0001641172-25-002917.md) | [(0.2)](/filings/0001493152-25-023619.md) | [(0.1)](/filings/0001493152-25-023619.md) | [(0.2)](/filings/0001493152-25-023619.md) | [(0.8)](/filings/0001493152-25-023619.md) | [(15.9)](/filings/0001493152-26-037819.md) | [(2.0)](/filings/0001493152-26-037819.md) | [(1.9)](/filings/0001493152-25-023619.md) | [(4.7) d](/filings/0001493152-26-015737.md) | [(3.2)](/filings/0001493152-26-037819.md) | [(1.3)](/filings/0001493152-26-037819.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | [(0.01)](/filings/0001493152-25-023619.md) | not reported | [(504.88)](/filings/0001493152-26-023802.md) | [(48.19)](/filings/0001493152-26-037819.md) | [(0.04)](/filings/0001493152-25-023619.md) | not reported | [(20.57)](/filings/0001493152-26-023802.md) | [(1.22)](/filings/0001493152-26-037819.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | [(0.01)](/filings/0001493152-25-023619.md) | not reported | [(504.88)](/filings/0001493152-26-023802.md) | [(48.19)](/filings/0001493152-26-037819.md) | [(0.04)](/filings/0001493152-25-023619.md) | not reported | [(20.57)](/filings/0001493152-26-023802.md) | [(1.22)](/filings/0001493152-26-037819.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.0](/filings/0001493152-23-039795.md) | not reported | [0.0](/filings/0001641172-25-023566.md) | not reported | not reported | [0.0](/filings/0001493152-26-015737.md) | [1.3](/filings/0001641172-25-023566.md) | [0.2](/filings/0001641172-25-023573.md) | [1.9](/filings/0001493152-25-023619.md) | [1.0](/filings/0001493152-26-037819.md) | [5.9](/filings/0001493152-26-023802.md) | [12.2](/filings/0001493152-26-037819.md) |
| Current assets | $m | [0.3](/filings/0001493152-23-039795.md) | [0.1](/filings/0001641172-25-002917.md) | [0.1](/filings/0001493152-24-022728.md) | [0.3](/filings/0001493152-24-032815.md) | [0.1](/filings/0001493152-24-045850.md) | [0.1](/filings/0001493152-26-015737.md) | [2.0](/filings/0001641172-25-023566.md) | [1.0](/filings/0001641172-25-023573.md) | [2.4](/filings/0001493152-25-023619.md) | [1.3](/filings/0001493152-26-037819.md) | [7.1](/filings/0001493152-26-023802.md) | [13.5](/filings/0001493152-26-037819.md) |
| Total assets | $m | [19.9](/filings/0001493152-23-039795.md) | [20.0](/filings/0001641172-25-002917.md) | [20.2](/filings/0001493152-24-022728.md) | [6.9](/filings/0001493152-24-032815.md) | [6.7](/filings/0001493152-24-045850.md) | [0.1](/filings/0001493152-26-015737.md) | [2.0](/filings/0001641172-25-023566.md) | [1.0](/filings/0001641172-25-023573.md) | [2.4](/filings/0001493152-25-023619.md) | [1.3](/filings/0001493152-26-037819.md) | [7.1](/filings/0001493152-26-023802.md) | [13.5](/filings/0001493152-26-037819.md) |
| Current liabilities | $m | [0.3](/filings/0001493152-23-039795.md) | [0.4](/filings/0001641172-25-002917.md) | [2.6](/filings/0001493152-24-022728.md) | [6.2](/filings/0001493152-24-032815.md) | [6.6](/filings/0001493152-24-045850.md) | [1.7](/filings/0001493152-26-015737.md) | [9.9](/filings/0001641172-25-023566.md) | [10.6](/filings/0001641172-25-023573.md) | [13.9](/filings/0001493152-25-023619.md) | [7.6](/filings/0001493152-26-037819.md) | [3.2](/filings/0001493152-26-023802.md) | [1.7](/filings/0001493152-26-037819.md) |
| Total liabilities | $m | [0.3](/filings/0001493152-23-039795.md) | [0.4](/filings/0001641172-25-002917.md) | [2.6](/filings/0001493152-24-022728.md) | [6.2](/filings/0001493152-24-032815.md) | [6.6](/filings/0001493152-24-045850.md) | [1.7](/filings/0001493152-26-015737.md) | [9.9](/filings/0001641172-25-023566.md) | [10.6](/filings/0001641172-25-023573.md) | [13.9](/filings/0001493152-25-023619.md) | [7.7](/filings/0001493152-26-037819.md) | [3.2](/filings/0001493152-26-023802.md) | [1.8](/filings/0001493152-26-037819.md) |
| Shareholders' equity | $m | [(0.1)](/filings/0001493152-24-045850.md) | [(0.5)](/filings/0001493152-25-023619.md) | [(0.5)](/filings/0001493152-25-023619.md) | [(0.6)](/filings/0001493152-25-023619.md) | [(0.8)](/filings/0001493152-25-023619.md) | [(1.5)](/filings/0001641172-25-023573.md) | [(8.0)](/filings/0001493152-26-037819.md) | [(9.6)](/filings/0001493152-26-037819.md) | [(11.5)](/filings/0001493152-25-023619.md) | [(6.4)](/filings/0001493152-26-037819.md) | [3.9](/filings/0001493152-26-037819.md) | [11.8](/filings/0001493152-26-037819.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(125) d](/filings/0001493152-24-045850.md) | [(156) d](/filings/0001641172-25-002917.md) | [(193)](/filings/0001641172-25-023566.md) | [(56.2) d](/filings/0001641172-25-023573.md) | [(496) d](/filings/0001493152-25-023619.md) | [480 d](/filings/0001493152-26-015737.md) | [(1,752)](/filings/0001493152-26-023802.md) | [(1,140) d](/filings/0001493152-26-037819.md) | [(1,104) d](/filings/0001493152-25-023619.md) | [(928) d](/filings/0001493152-26-015737.md) | [(3,039)](/filings/0001493152-26-023802.md) | [(2,116) d](/filings/0001493152-26-037819.md) |
| Share repurchases | $k | [633 d](/filings/0001493152-24-045850.md) | [0.0 d](/filings/0001641172-25-002917.md) | not reported | not reported | [0.0 d](/filings/0001493152-24-045850.md) | [0.0 d](/filings/0001641172-25-002917.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.6](/filings/0001493152-25-023619.md) | [0.0](/filings/0001493152-26-023802.md) | [0.0](/filings/0001493152-26-037819.md) | [49.5](/filings/0001493152-25-023619.md) | [0.2](/filings/0001493152-26-023802.md) | [1.0](/filings/0001493152-26-037819.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,402,557 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001493152-26-037819.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.